AstraZeneca PLC (AZN)vsBiogen Inc (BIIB)
AZN
AstraZeneca PLC
$160.17
+0.33%
HEALTHCARE · Cap: $252.33B
BIIB
Biogen Inc
$217.15
+0.80%
HEALTHCARE · Cap: $31.40B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 512% more annual revenue ($61.37B vs $10.03B). AZN leads profitability with a 17.0% profit margin vs 8.3%. BIIB appears more attractively valued with a PEG of 1.16. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
BIIB
Buy55
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+18.4%
Fair Value
$196.10
Current Price
$160.17
$35.93 discount
Margin of Safety
+37.5%
Fair Value
$305.78
Current Price
$217.15
$88.63 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Reasonable price relative to book value
Strong operational efficiency at 25.1%
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
Premium valuation, high expectations priced in
3.4% revenue growth
ROE of 4.4% — below average capital efficiency
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bull Case : BIIB
The strongest argument for BIIB centers on Price/Book, Operating Margin. PEG of 1.16 suggests the stock is reasonably priced for its growth.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : BIIB
The primary concerns for BIIB are P/E Ratio, Revenue Growth, Return on Equity.
Key Dynamics to Monitor
AZN profiles as a mature stock while BIIB is a value play — different risk/reward profiles.
AZN carries more volatility with a beta of 0.20 — expect wider price swings.
AZN is growing revenue faster at 6.4% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 55/100), backed by strong 17.0% margins. BIIB offers better value entry with a 37.5% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Biogen Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?